Evidence map›Paper›PMID 26164495›Full record

Trial reportGastroenterology2015

Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome: A Crossover Trial.

Daniel E Freedberg, Nora C Toussaint, Sway P Chen, Adam J Ratner, Susan Whittier, Timothy C Wang, Harris H Wang, Julian A Abrams

2 registry-linked trialsOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 167 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
167citing papers in PubMed, 6 pooled it
17.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01901276 phase4completednot on this map

The Effects of Gastric Acid Suppression on the Colonic Microbiome

TypeinterventionalSponsorDaniel Freedberg, MDRan2013 to 2015Enrolled14ConditionsClostridium DifficileArmsOmeprazole 40 mg bid
NCT02893709 nacompletednot on this map

Factors Influencing the Human Gut Microbiome Profile in Multi-ethnic Groups of the Singapore Community (FAMES)

TypeinterventionalSponsorChangi General HospitalRan2015 to 2016Enrolled36ConditionsGastroesophageal Reflux DiseaseArmsOmeprazole
3 · Its place in the literature

Who cites it

167 citing papers in PubMed, 6 syntheses or guidelines pooled it, 310 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

107 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Daniel E FreedbergDepartment of Medicine, Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, New York.
Nora C ToussaintNew York Genome Center, New York, New York.
Sway P ChenCollege of Physicians and Surgeons, Columbia University Medical Center, New York, New York.
Adam J RatnerDepartment of Pediatrics, Division of Infectious Diseases, Columbia University Medical Center, New York, New York.
Susan WhittierDepartment of Pathology and Cell Biology, Columbia University, New York, New York.
Timothy C WangDepartment of Medicine, Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, New York.
Harris H WangDepartment of Pathology and Cell Biology, Columbia University, New York, New York; Department of Systems Biology, Columbia University, New York, New York. Electronic address: hw2429@cumc.columbia.edu.
Julian A AbramsDepartment of Medicine, Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, New York. Electronic address: ja660@cumc.columbia.edu.
Columbia University Irving Medical Center · USColumbia University · USNew York Genome Center · US

Funding

Clinical and Translational Science AwardKL2TR000081 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$3.3M
Functional Metagenomic Reprogramming of the Human Microbiome through Mobilome EngDP5OD009172 · OD · HARVARD MEDICAL SCHOOL · PI WANG, HARRIS H · 2011 to 2015
$2.0M
NCATS NIH HHS KL2 TR000081NIH HHS 1DP5OD009172-02NIH HHS DP5 OD009172
6 · The paper itself

Abstract

We conducted an open-label crossover trial to test whether proton pump inhibitors (PPIs) affect the gastrointestinal microbiome to facilitate Clostridium difficile infection (CDI). Twelve healthy volunteers each donated 2 baseline fecal samples, 4 weeks apart (at weeks 0 and 4). They then took PPIs for 4 weeks (40 mg omeprazole, twice daily) and fecal samples were collected at week 8. Six individuals took the PPIs for an additional 4 weeks (from week 8 to 12) and fecal samples were collected from all subjects at week 12. Samples were analyzed by 16S ribosomal RNA gene sequencing. We found no significant within-individual difference in microbiome diversity when we compared changes during baseline vs changes on PPIs. There were, however, significant changes during PPI use in taxa associated with CDI (increased Enterococcaceae and Streptococcaceae, decreased Clostridiales) and taxa associated with gastrointestinal bacterial overgrowth (increased Micrococcaceae and Staphylococcaceae). In a functional analysis, there were no changes in bile acids on PPIs, but there was an increase in genes involved in bacterial invasion. These alterations could provide a mechanism by which PPIs predispose to CDI. ClinicalTrials.gov ID NCT01901276.

Indexed as

MicrobiotaBacteriaClostridioides difficileCross-Over StudiesDrug Administration ScheduleEnterocolitis, PseudomembranousFecesHealthy VolunteersHumansIntestinesOmeprazoleProton Pump InhibitorsRibotypingRisk FactorsTime FactorsOmeprazoleProton Pump InhibitorsAcid SuppressionClostridium difficile InfectionGastroesophageal Reflux DiseasePharmacology

Identifiers

PMID26164495
PMCPMC4584196
OpenAlexW2153294515

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.